In the local area, access to medication abortion remains a topic of interest. A recent court decision has given the FDA a deadline to provide an update on its review. The FDA has been instructed to file a report by October 7, 2026, detailing the status of its review and any changes to its completion timeline. For now, clinicians are allowed to continue mailing mifepristone to patients seeking abortions, regardless of the patient's location, while the review is ongoing. Further information on this topic is available from the KFF Women's Health Policy.
choice
The Latest on Medication Abortion Access: The Court Awaits the FDA Review
In the local area, access to medication abortion remains a topic of interest. A recent court decision has given the FDA a deadline to provide an update on its review. The FDA has been instructed to fi